{
    "nctId": "NCT03027245",
    "briefTitle": "Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy",
    "officialTitle": "Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE)",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced or Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 353,
    "primaryOutcomeMeasure": "Number of participants experiencing eribulin-induced peripheral neuropathy (PN)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced or MBC with progression after at least one chemotherapeutic regimen for advanced disease eligible for treatment with eribulin according to Fachinformation. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless participants were not suitable for these treatments\n* 1-3 prior chemotherapeutic regimens for advanced disease\n* Age \\>=18 years at the time of Informed Consent\n* Ability to understand and willingness to respond to questions related to their health\n* Decision for the participant to start treatment with eribulin has been made prior to inclusion in this study.\n* Signed written Informed Consent\n\nExclusion Criteria:\n\n* Previous treatment with eribulin in any line of treatment\n* Contraindication according to the Fachinformation of eribulin\n* Pregnancy or lactation\n* Participation in an interventional clinical trial at the same time",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}